Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a Phase 3 study

Journal of the European Academy of Dermatology and Venereology

Volumn 30, Issue 10, 2016, Pages 1753-1759

  Valenzuela, F ^a   Paul, C ^b   Mallbris, L ^c   Tan, H ^c   Papacharalambous, J ^c   Valdez, H ^c   Mamolo, C ^c  

^a UNIVERSITY OF CHILE   (Chile)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; PLACEBO; TOFACITINIB; DERMATOLOGICAL AGENT; PIPERIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; ARTICLE; CONTROLLED STUDY; DERMATOLOGY LIFE QUALITY INDEX; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PATIENT-REPORTED OUTCOME; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; PSORIASIS VULGARIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; CHRONIC DISEASE; CLINICAL TRIAL; PATIENT SATISFACTION; PSORIASIS; TREATMENT OUTCOME;

CHRONIC DISEASE; DERMATOLOGIC AGENTS; ETANERCEPT; HUMANS; PATIENT SATISFACTION; PIPERIDINES; PLACEBOS; PSORIASIS; PYRIMIDINES; PYRROLES; TREATMENT OUTCOME;

EID: 84977510874     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.13702     Document Type: Article

References (31)

1. Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005; 64(Suppl 2): ii18–ii23.
2. Gordon KB, Langley RG, Leonardi C et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006; 55: 598–606.
3. Reich K, Nestle FO, Papp K et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367–1374.
4. Kimball AB, Papp KA, Wasfi Y et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol 2013; 27: 1535–1545.
5. Yosipovitch G, Goon A, Wee J, Chan YH, Goh CL. The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis. Br J Dermatol 2000; 143: 969–973.
6. Reich A, Hrehorów E, Szepietowski JC. Pruritus is an important factor negatively influencing the well-being of psoriatic patients. Acta Derm Venereol 2010; 90: 257–263.
7. Strand V, Fiorentino D, Hu C, Day RM, Stevens RM, Papp KA. Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study. Health Qual Life Outcomes 2013; 11: 82.
8. Mamolo C, Harness J, Tan H, Menter A. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol 2014; 28: 192–203.
9. Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the national psoriasis foundation surveys, 2003–2011. JAMA Dermatol 2013; 149: 1180–1185.
10. Krueger GG, Langley RG, Finlay AY et al. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol 2005; 153: 1192–1199.
11. Saurat JH, Stingl G, Dubertret L et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158: 558–566.
12. Revicki D, Willian MK, Saurat JH et al. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatol 2008; 158: 549–557.
13. Bachelez H, van de Kerkhof PCM, Strohal R et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet 2015; 386: 552–561.
14. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210–216.
15. Mrowietz U, Kragballe K, Reich K et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303: 1–10.
16. Mamolo CM, Bushmakin AG, Capelleri JC. Application of the Itch Severity Score in patients with moderate-to-severe plaque psoriasis: clinically important difference and responder analyses. J Dermatolog Treat 2015; 26: 121–123.
17. Maruish ME. User's Manual for the SF-36v2 Health Survey. QualityMetric Incorporated, Lincoln, RI, 2011.
18. Ware JE, Kosinski M, Dewey JE. How to Score Version Two of the SF 36 Health Survey. Quality Metric, Incorporate, Lincoln, RI, 2000.
19. Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Invest Dermatol 2005; 125: 659–664.
20. Gordon KB, Kimball AB, Chau D et al. Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory. Br J Dermatol 2014; 170: 705–715.
21. Eghlileb AM, Davies EE, Finlay AY. Psoriasis has a major secondary impact on the lives of family members and partners. Br J Dermatol 2007; 156: 1245–1250.
22. Maza A, Richard MA, Aubin F et al. Significant delay in the introduction of systemic treatment of moderate to severe psoriasis: a prospective multicentre observational study in outpatients from hospital dermatology departments in France. Br J Dermatol 2012; 167: 643–648.
23. Paul C, Bushmakin AG, Cappelleri JC, Mallbris L, Mamolo C. Do Patients and Physicians Agree in Their Assessment of the Severity of Psoriasis? Insights from Tofacitinib Phase 3 Clinical Trials. J Dermatolog Clin Res 2015; 3: 1048.
24. AMGEN Inc. Etanercept (Enbrel) - US Prescribing Information. [WWW document] 2013. URL http://www.enbrel.com/index.jspx (last accessed: 19 May 2016).
25. Smith CH, Anstey AV, Barker JN et al. British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009; 161: 987–1019.
26. Basra MK, Fenech R, Gatt RM, Salek MS, Finlay AY. The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol 2008; 159: 997–1035.
27. Mazzotti E, Picardi A, Sampogna F, Sera F, Pasquini P, Abeni D. Sensitivity of the Dermatology Life Quality Index to clinical change in patients with psoriasis. Br J Dermatol 2003; 149: 318–322.
28. Basra MK, Salek MS, Camilleri L, Sturkey R, Finlay AY. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Br J Dermatol 2015; 230: 27–33.
29. Lebwohl MG, Bachelez H, Barker J et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol 2014; 70: 871–881.
30. Lewis-Beck C, Abouzaid S, Xie L, Baser O, Kim E. Analysis of the relationship between psoriasis symptom severity and quality of life, work productivity, and activity impairment among patients with moderate-to-severe psoriasis using structural equation modeling. Patient Prefer Adherence 2013; 7: 199–205.
31. Papp KA, Menter MA, Abe M et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two, randomised, placebo-controlled, Phase 3 trials. Br J Dermatol 2015; 173: 949–961.